Ritanserin

Ritanserin
Clinical data
Other names	R-55667; R55667; Tiserton
Routes of; administration	Oral
Drug class	Serotonin 5-HT2 receptor antagonist; Serotonin 5-HT2A receptor antagonist
ATC code	None;
Pharmacokinetic data
Onset of action	1.7 hours (TmaxTooltip time to peak levels)
Elimination half-life	54 hours
Identifiers
	IUPAC name 6-[2-[4-[bis(4-fluorophenyl)methylidene]piperidin-1-yl]ethyl]-7-methyl-[1,3]thiazolo[2,3-b]pyrimidin-5-one;
CAS Number	87051-43-2 ;
PubChem CID	5074;
IUPHAR/BPS	97;
ChemSpider	4896 ;
UNII	145TFV465S;
ChEBI	CHEBI:64195 ;
ChEMBL	ChEMBL267777 ;
CompTox Dashboard (EPA)	DTXSID9042594 ;
ECHA InfoCard	100.163.772
Chemical and physical data
Formula	C27H25F2N3OS
Molar mass	477.57 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C(C(=O)N2C=CSC2=N1)CCN3CCC(=C(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F)CC3;
	InChI InChI=1S/C27H25F2N3OS/c1-18-24(26(33)32-16-17-34-27(32)30-18)12-15-31-13-10-21(11-14-31)25(19-2-6-22(28)7-3-19)20-4-8-23(29)9-5-20/h2-9,16-17H,10-15H2,1H3 ; Key:JUQLTPCYUFPYKE-UHFFFAOYSA-N ;
	(what is this?) (verify)

Ritanserin, also known by its developmental code name R-55667, is a serotonin receptor antagonist which was under development for the treatment of anxiety disorders and major depressive disorder but was never marketed. It was also investigated for treatment of insomnia, especially to enhance sleep quality by significantly increasing slow wave sleep by virtue of potent and concomitant serotonin 5-HT_2A and 5-HT_2C receptor antagonism. The drug is taken orally.